Metabolomic Identification of Subtypes of Nonalcoholic Steatohepatitis

Adult Male 0301 basic medicine S-Adenosylmethionine Knockout Clinical Sciences Chronic Liver Disease and Cirrhosis 610 Clinical sciences Inbred C57BL Prognostic Ceramides Oral and gastrointestinal Hepatitis Paediatrics and Reproductive Medicine Diglycerides Mice 03 medical and health sciences Non-alcoholic Fatty Liver Disease 616 Animals Humans Triglycerides Mice, Knockout Mouse Model Biomedical and Clinical Sciences Gastroenterology & Hepatology Liver Disease Fatty Acids Neurosciences Methionine Adenosyltransferase Middle Aged Lipid Metabolism 4.1 Discovery and preclinical testing of markers and technologies 1-Carbon Metabolism 3. Good health Nutrition and dietetics Mice, Inbred C57BL Metabolome Female Digestive Diseases Biomarkers
DOI: 10.1053/j.gastro.2017.01.015 Publication Date: 2017-01-26T16:48:48Z
ABSTRACT
Nonalcoholic fatty liver disease (NAFLD) is a consequence of defects in diverse metabolic pathways that involve hepatic accumulation of triglycerides. Features of these aberrations might determine whether NAFLD progresses to nonalcoholic steatohepatitis (NASH). We investigated whether the diverse defects observed in patients with NAFLD are caused by different NAFLD subtypes with specific serum metabolomic profiles, and whether these can distinguish patients with NASH from patients with simple steatosis.We collected liver and serum from methionine adenosyltransferase 1a knockout (MAT1A-KO) mice, which have chronically low levels of hepatic S-adenosylmethionine (SAMe) and spontaneously develop steatohepatitis, as well as C57Bl/6 mice (controls); the metabolomes of all samples were determined. We also analyzed serum metabolomes of 535 patients with biopsy-proven NAFLD (353 with simple steatosis and 182 with NASH) and compared them with serum metabolomes of mice. MAT1A-KO mice were also given SAMe (30 mg/kg/day for 8 weeks); liver samples were collected and analyzed histologically for steatohepatitis.Livers of MAT1A-KO mice were characterized by high levels of triglycerides, diglycerides, fatty acids, ceramides, and oxidized fatty acids, as well as low levels of SAMe and downstream metabolites. There was a correlation between liver and serum metabolomes. We identified a serum metabolomic signature associated with MAT1A-KO mice that also was present in 49% of the patients; based on this signature, we identified 2 NAFLD subtypes. We identified specific panels of markers that could distinguish patients with NASH from patients with simple steatosis for each subtype of NAFLD. Administration of SAMe reduced features of steatohepatitis in MAT1A-KO mice.In an analysis of serum metabolomes of patients with NAFLD and MAT1A-KO mice with steatohepatitis, we identified 2 major subtypes of NAFLD and markers that differentiate steatosis from NASH in each subtype. These might be used to monitor disease progression and identify therapeutic targets for patients.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (39)
CITATIONS (230)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....